Effect of acetazolamide on insulin sensitivity in myotonic disorders.
Acetazolamide is effective treatment for myotonia in certain patients with myotonia congenita. Since potassium metabolism may be abnormal in myotonia congenita, we studied the effect of acetazolamide administration on potassium regulation and glucose disposal, using the euglycemic insulin clamp technique in patients with myotonic disorders and in normal subjects. Glucose disposal was normal in patients with myotonia congenita; administration of acetazolamide increased glucose disposal in normal subjects and in patients with myotonia congenita. By contrast, patients with myotonic dystrophy showed insulin resistance and decreased glucose disposal that was not improved by acetazolamide administration. Patients with myotonia congenita had elevated potassium levels in the basal state and a greater fall in potassium level during the insulin clamp procedure than controls. Patients with myotonic dystrophy had normal or low basal potassium levels and a subnormal decrease in potassium level during the insulin clamp procedure. Administration of acetazolamide did not alter these abnormalities in potassium metabolism in patients with either myotonia congenita or myotonic dystrophy.
D000086:Acetazolamide / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D005260:Female; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009224:Myotonia Congenita / Q000188:drug therapy* / Q000378:metabolism; D009223:Myotonic Dystrophy / Q000188:drug therapy* / Q000378:metabolism; D011188:Potassium / Q000378:metabolism
D007328:Insulin; D005947:Glucose; D000086:Acetazolamide; D011188:Potassium